Status:
TERMINATED
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
Lead Sponsor:
Escient Pharmaceuticals, Inc
Conditions:
Chronic Spontaneous Urticaria
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria
Eligibility Criteria
Inclusion
- Documented history of chronic spontaneous urticaria (CSU) with a UAS7 greater than or equal to 16 despite stable treatment with H1 antihistamine consistent with standard of care
- Must be on a stable dose of H1 antihistamine up to 4 times the approved dose per local treatment guidelines
Exclusion
- Urticaria with a clear underlying etiology other than CSU
- Urticaria with a clearly defined or sole trigger (chronic inducible urticaria)
- Other active skin diseases associated with chronic pruritus (eg, atopic dermatitis, bullous pemphigoid, prurigo nodularis, dermatitis herpetiformis)
Key Trial Info
Start Date :
September 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 16 2025
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT06077773
Start Date
September 25 2023
End Date
January 16 2025
Last Update
December 19 2025
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
AllerVie Clinical Research
Birmingham, Alabama, United States, 35209
2
Scottsdale Clinical Trials
Scottsdale, Arizona, United States, 85260
3
Little Rock Allergy & Asthma Clinical Research Center
Little Rock, Arkansas, United States, 72205
4
First OC Dermatology Research, Inc.
Fountain Valley, California, United States, 92708